✦ LIBER ✦

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

✍ Scribed by J.-P. Ortonne; A. Taïeb; A.D. Ormerod; D. Robertson; J. Foehl; R. Pedersen; C. Molta; B. Freundlich

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of inflammatory markers in asse

✍ A. Kanelleas; C. Liapi; A. Katoulis; P. Stavropoulos; G. Avgerinou; S. Georgala; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Efficacy and safety of briakinumab vs. e

✍ A.B. Gottlieb; C. Leonardi; F. Kerdel; S. Mehlis; M. Olds; D.A. Williams 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

Relationship between methotrexate dosing

✍ J.-H. Saurat; R.G. Langley; K. Reich; K. Unnebrink; E.H. Sasso; W. Kampman 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

Switching to adalimumab in patients with

✍ R.T. Woolf; C.H. Smith; K. Robertson; J.N.W.N. Barker 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

Safety of Efalizumab in Patients with Mo

✍ Kim A. Papp; Charles Camisa; Stephen P. Stone; Ivor Caro; Xiaolin Wang; Peter Co 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 139 KB

Once weekly administration of etanercept

✍ P.C.M. Van De Kerkhof; S. Segaert; M. Lahfa; T.A. Luger; Z. Karolyi; A. Kaszuba; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB